Single-Center Real-World Experience with Primary Central Nervous System Lymphoma in the 21st Century
- Author:
Hyungwoo CHO
1
;
Jung Yong HONG
;
Dae Ho LEE
;
Shin KIM
;
Kyoungmin LEE
;
Eun Hee KANG
;
Sunjong LEE
;
Jung Sun PARK
;
Jeong Hoon KIM
;
Jin Sook RYU
;
Jooryung HUH
;
Cheolwon SUH
Author Information
- Publication Type:1
- From:Korean Journal of Medicine 2024;99(1):37-49
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Background/Aims:In Korea, the incidence of primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is increasing and autologous stem cell transplantation (ASCT) has improved the survival of younger patients. We explored our real-world experience with PCNSL at Asan Medical Center (AMC).
Methods:We used the AMC lymphoma registry to collect patient data prospectively. We analyzed 279 patients diagnosed from 2002 until August 2019.
Results:The PCNSL incidence at AMC increased progressively and comprised 7.4-8.9% of new non-Hodgkin lymphoma patients annually during the most recent 4 years. The median age was 60 years (range, 17-85) and males comprised 55%. Patients under 65 years of age (n = 183) had no significant differences in characteristics compared to those aged 65 years or over, with the exception of less occipital lobe involvement and lower beta-2 microglobulin levels. Rituximab, methotrexate, procarbazine, and vincristine (R-MPV) combination induction had the best overall response, of 95%. The median overall survival was 3.8 years with 5- and 10-year survival rates of 41.5% and 30.2%, respectively. Survival was better in younger patients and those treated with ASCT. Thiotepa, busulfan, and cytoxan (TBC) conditioning chemotherapy had better survival than other combinations. The International Extranodal Lymphoma Study Group and Memorial Sloan Kettering Cancer Center prognostic score systems were valid in this cohort. Age and performance status were independent prognostic factors. Exclusive extra-central nervous system failure occurred in six patients (5.6%) among 107 failures.
Conclusions:The incidence of PCNSL is rising. R-MPV induction therapy followed by ASCT with TBC has improved the survival of young, fit PCNSL patients.
